AI · SEMICONDUCTOR · FACT CHECK
SKD WIRETrue
OpenAI has acquired Orchestra Bio as part of an effort to reinforce its AI capabilities in new drug development, the company said.
The acquisition of Orchestra Bio reflects OpenAI's push to apply its AI technology to new drug development. Details such as the transaction value were not disclosed, and the company did not provide additional information about how Orchestra Bio's assets will be integrated.
The move adds to a growing line of applications where large AI models are deployed beyond conventional software tasks, with pharmaceutical research emerging as a key area.
No timeline for integration or specific product plans were announced. As with other parts of the deal, aspects of the acquisition remain unconfirmed pending further disclosure by the parties involved.
The claim that OpenAI acquired Orchestra Bio to strengthen its AI for new drug development is True.
Verdict: True
